

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 2, 2024 (December 26, 2023)

**RenovoRx, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other Jurisdiction  
of Incorporation)

001-40738  
(Commission  
File Number)

27-1448452  
(IRS Employer  
Identification No.)

4546 El Camino Real, Suite B1  
Los Altos, CA 94022  
(650) 284-4433

(Address and telephone number, including area code, of registrant's principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events**

RenovoRx, Inc. (the "Company") reports with great sadness the passing of David Diamond on December 26, 2023. Mr. Diamond served the Company with distinction since May 2021 as a member of the Company's Board of Directors (the "Board") and will be greatly missed. Mr. Diamond served as Chair of the Audit Committee of the Board, as a member of the Compensation Committee of the Board and as the Lead Independent Director. In due course, the Board will seek a replacement for Mr. Diamond.

The Company extends its deepest sympathies to the Diamond family.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**RenovoRx, Inc.**

Date: January 2, 2024

By: /s/ Shaun Bagai  
Name: Shaun R. Bagai  
Title: Chief Executive Officer